- Same Thing
- Side Effects
- What Is
- Drug Interactions
Are Rinvoq and Otezla the Same Thing?
Otezla is used to treat adults with active psoriatic arthritis.
Rinvoq and Otezla belong to different drug classes. Rinvoq is a Janus kinase (JAK) inhibitor and Otezla is a phosphodiesterase 4 (PDE4) inhibitor.
Side effects of Rinvoq that are different from Otezla include fever.
Side effects of Otezla that are different from Rinvoq include diarrhea, headache, runny or stuffy nose, abdominal pain, fatigue, indigestion/heartburn, decreased appetite, insomnia, back pain, frequent bowel movements, depression, bronchitis, tooth abscess, sinus headache, hypersensitivity, weight loss, gastroesophageal reflux disease (GERD), migraine, and rash.
Both Rinvoq and Otezla may interact with strong CYP3A4 inducers (e.g., rifampin).
What Are Possible Side Effects of Rinvoq?
Common side effects of Rinvoq include:
- upper respiratory tract infections,
- cough, and
What Are Possible Side Effects of Otezla?
Common side effects of Otezla include:
What Is Rinvoq?
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
What Is Otezla?
Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor used to treat adult patients with active psoriatic arthritis.
What Drugs Interact With Rinvoq?
Rinvoq may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines. Tell your doctor all medications and supplements you use. Rinvoq is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rinvoq and for 4 weeks following completion of therapy. It is unknown if Rinvoq passes into breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Rinvoq, and for 6 days after the last dose.
How Should Rinvoq be Taken?
The recommended dose of Rinvoq is 15 mg once daily. Rinvoq may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.
All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).
Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.
Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.
The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.
As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.
Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.
If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.
You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.
Celgene Corporation. Otezla Product Information.